TokenPost·
Aktis Oncology’s Q3 Net Loss Nearly Doubles to $29.9 Million
Research and development expenses rose to $32.1 million as the company began a third Phase 1b trial and expects its cash to fund operations into 2029.
More news
- crypto.newsEthereum price slips below $2,000 as traders debate a rebound
- TokenPostChagee Approves About $1.95 Special Dividend, Sets Three-Year Payout Plan
- DecryptNvidia, AMD, Broadcom: The AI Stock Winners and Losers After Jensen Huang’s Ousting
- TokenPostSoFiUSD Adds Polygon for In-App Access on a Third Blockchain
- TokenPostNvidia Contracts Led Hyperliquid’s Nov. 12 Volume Ranking With $1.5 Billion
- Crypto BriefingInstitutional ownership of Nvidia falls 46.01% quarter over quarter to 23.7%